Related Experiment Video
Updated: Jul 26, 2026

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
Published on: February 24, 2014
Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin
1Department of Chemistry, Massachusetts Institute of Technology, Cambridge 02139.
Abstract:
The mechanism of action of the anticancer compound cis-diamminedichloroplatinum(II) (cisplatin) involves covalent binding to DNA. In an effort to understand the tumor-specific cytotoxicity of such DNA damage, the interactions of these lesions with cellular proteins have been studied. One such protein has been identified as the high-mobility group protein HMG1. Recombinant rat HMG1 binds specifically (dissociation constant 3.7 +/- 2.0 x 10(-7) molar) to DNA containing cisplatin d(GpG) or d(ApG) intrastrand cross-links, which unwind and bend DNA in a specific manner, but not to DNA modified by therapeutically inactive platinum analogs. These results suggest how HMG1 might bind to altered DNA structures and may be helpful in designing new antitumor drugs.
Insights
High-mobility group protein 1 (HMG1) specifically binds to DNA damaged by the anticancer drug cisplatin. This interaction with cisplatin-induced DNA lesions may explain tumor-specific effects and aid in new drug design.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Development
Background:
- Cisplatin is an anticancer drug that functions by covalently binding to DNA.
- Understanding how DNA damage from cisplatin leads to tumor-specific cell death is crucial.
- Cellular proteins interacting with these DNA lesions are key to this understanding.
Purpose of the Study:
- To investigate the interaction between cisplatin-induced DNA damage and cellular proteins.
- To identify specific proteins that recognize and bind to DNA modified by cisplatin.
- To elucidate the role of such interactions in the mechanism of action of cisplatin.
Main Methods:
- Utilized recombinant rat high-mobility group protein 1 (HMG1).
- Assessed the binding affinity of HMG1 to DNA containing specific cisplatin-induced intrastrand cross-links (d(GpG) and d(ApG)).
- Compared binding to DNA modified by active cisplatin versus inactive platinum analogs.
Main Results:
- Recombinant rat HMG1 demonstrated specific binding to DNA with cisplatin d(GpG) or d(ApG) intrastrand cross-links.
- The dissociation constant for HMG1 binding to these lesions was measured at 3.7 +/- 2.0 x 10(-7) M.
- HMG1 did not bind to DNA modified by therapeutically inactive platinum analogs.
Conclusions:
- HMG1 specifically recognizes and binds to DNA structures altered by cisplatin.
- The specific binding of HMG1 to cisplatin-damaged DNA suggests a role in mediating the drug's effects.
- These findings provide insights into the mechanism of cisplatin cytotoxicity and can inform the design of novel antitumor agents.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Treatment Resistant Cancers
DNA Damage Can Stall the Cell Cycle

